Obesity – Current Treatment – Treatment Algorithms: Claims Data Analysis – Obesity (US)
GLP-1 RA products have set new standards for weight-loss drugs and are driving the rapid growth of the obesity market. Novo Nordisk’s semaglutide (Wegovy) and Eli Lilly’s tirzepatide (Zepbound) are the market-leading obesity drugs, providing broad clinical benefits and far superior weight loss compared with legacy therapies. These legacy treatments, which include noradrenergic anorectics, lipase inhibitors, and the GLP-1 RA liraglutide, are losing ground as products of choice. This report provides in-depth analysis and insight into how prescription weight-loss drugs are used for obesity and how medical practice is evolving.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed obesity patients?
- What are the quarterly trends in prescribing among recently treated and newly diagnosed obesity patients?
- How have the GLP-1 RA products been integrated into the treatment algorithm, and what is their source of business?
- What percentage of obesity patients receive drug therapy within one year of diagnosis?
- What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of obesity patients are treated with monotherapy vs. combination therapy? What are the most used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
Key drugs covered
Tirzepatide, semaglutide, liraglutide, phentermine + topiramate FDC, naltrexone + bupropion FDC, orlistat
Key analyses
- Brand / therapy usage across patient sample
- Newly diagnosed patient analysis
- Treatment initiation and progression
- Line of therapy analysis
- Combination therapy analysis
- Source of business for recently treated patients
- Persistency and compliance analysis
- Product-level patient flow
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses
